AEON Biopharma, Inc.

AEON Biopharma has regained compliance with NYSE American continued listing standards after resolving stockholders' equity deficiencies. The company received written confirmation from NYSE Regulation on August 3, 2026, that it had cured the previously identified issues under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide. The compliance was achieved following an underwritten public offering that closed on July 15, 2026, which included 17,851,599 shares of common stock and pre-funded warrants to purchase 24,837,008 shares, with an additional 4,696,102 shares sold on July 23, 2026 through a partial exercise of the underwriters' over-allotment option. The offering generated aggregate net proceeds of approximately $13.6 million, with the potential for up to an additional $34.0 million in gross proceeds upon full cash exercise of milestone warrants. As a result, AEON believes its stockholders' equity now exceeds the $4.0 million minimum requirement, and the company expects the below-compliance indicator to be removed from its trading symbol.